Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;101:e225

This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, T. O.
Right arrow Articles by Ferguson, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, T. O.
Right arrow Articles by Ferguson, J. J.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Anticoagulant mechanisms
Right arrow Anticoagulants
Right arrow Coagulation and fibronolysis

(Circulation. 2000;101:e225.)
© 2000 American Heart Association, Inc.


Circulation Electronic Pages

Coumadin Versus Warfarin

Tsung O. Cheng, MD

Professor of Medicine The George Washington University, Washington, DC 20037


*    Introduction
up arrowTop
*Introduction
down arrowReferences
down arrowIntroduction 
down arrowReferences 
 
To the Editor:

I hate to write a letter to the editor to comment on another letter to the editor, especially if the author of the latter is a respected colleague of mine. However, in this case, I must make an important point regarding conformity to accepted writing style.

Ferguson1 in his sobering letter on the Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study used the words coumadin and warfarin interchangeably, without initially capitalizing the word Coumadin. Coumadin is the trademarked or brand name for the drug whose generic name is warfarin.

The Instructions to Authors of Circulation specify that generic rather than trademarked names be given. In addition, according to the American Medical Association Manual of Style,2 "Proprietary names (trademarks or brand names) use initial capitals... When both the nonproprietary (or generic) and proprietary (or brand) names are listed in the text, the nonproprietary names should be listed first, with the proprietary names capitalized and in parentheses."

Incidentally, warfarin itself is a hybrid word incorporating an acronym of the patent holder, Wisconsin Alumni Research Foundation, together with the suffix "-arin," denoting a relation to coumarin.


*    References
up arrowTop
up arrowIntroduction
*References
down arrowIntroduction 
down arrowReferences 
 
1. Ferguson JJ. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction. Circulation. 1999;99:2968. Letter.[Free Full Text]

2. American Medical Association Manual of Style. 9th ed. Baltimore, Md: Williams & Wilkins; 1998:355–356.

Response

James J. Ferguson, MD

Cardiology Research, MC 1-191 Texas Heart Institute, 1101 Bates St, Houston, TX 77030


*    Introduction 
up arrowTop
up arrowIntroduction
up arrowReferences
*Introduction 
down arrowReferences 
 
Dr Cheng is absolutely correct in pointing out the distinction between the generic name warfarin and the trade name Coumadin. The original Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study articleR1 correctly used the term warfarin throughout, but it did not specify the drug supplier. My letterR2 did not.

For readers interested in learning more about the history of drug development, including aspirin, heparin, warfarin, and thrombolytic agents, a review by Mueller and SchneidtR3 provides a wonderful overview. I promise to reread it.


*    References 
up arrowTop
up arrowIntroduction
up arrowReferences
up arrowIntroduction 
*References 
 
1. Anand SS, Yusuf S, Pogue J, et al. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: OASIS Pilot Study results. Circulation.. 1998;98:1064–1070.[Abstract/Free Full Text]

2. Ferguson JJ. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction. Circulation. 1999;99:2968. Letter.

3. Mueller RL, Scheidt S. History of drugs for thrombotic disease: discovery, development, and directions for the future. Circulation. 1994;89:432–449.[Abstract/Free Full Text]





This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, T. O.
Right arrow Articles by Ferguson, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, T. O.
Right arrow Articles by Ferguson, J. J.
Related Collections
Right arrow Cardiovascular Pharmacology
Right arrow Anticoagulant mechanisms
Right arrow Anticoagulants
Right arrow Coagulation and fibronolysis